Annual EBITDA
-$28.58 M
-$601.00 K-2.15%
December 31, 2023
Summary
- As of February 6, 2025, TRVI annual EBITDA is -$28.58 million, with the most recent change of -$601.00 thousand (-2.15%) on December 31, 2023.
- During the last 3 years, TRVI annual EBITDA has risen by +$3.69 million (+11.43%).
- TRVI annual EBITDA is now -199.61% below its all-time high of -$9.54 million, reached on December 31, 2017.
Performance
TRVI EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$13.24 M
-$915.00 K-7.43%
September 30, 2024
Summary
- As of February 6, 2025, TRVI quarterly EBITDA is -$13.24 million, with the most recent change of -$915.00 thousand (-7.43%) on September 30, 2024.
- Over the past year, TRVI quarterly EBITDA has dropped by -$5.47 million (-70.48%).
- TRVI quarterly EBITDA is now -235.00% below its all-time high of -$3.95 million, reached on March 31, 2018.
Performance
TRVI Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$44.20 M
-$5.56 M-14.40%
September 30, 2024
Summary
- As of February 6, 2025, TRVI TTM EBITDA is -$44.20 million, with the most recent change of -$5.56 million (-14.40%) on September 30, 2024.
- Over the past year, TRVI TTM EBITDA has dropped by -$15.61 million (-54.62%).
- TRVI TTM EBITDA is now -1018.58% below its all-time high of -$3.95 million, reached on March 31, 2018.
Performance
TRVI TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
TRVI EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -2.1% | -70.5% | -54.6% |
| 3 y3 years | +11.4% | -90.8% | -31.2% |
| 5 y5 years | -39.6% | -79.9% | -69.3% |
TRVI EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -2.1% | +12.6% | -152.8% | at low | -69.6% | at low |
| 5 y | 5-year | -9.8% | +12.6% | -152.8% | at low | -69.6% | at low |
| alltime | all time | -199.6% | +12.6% | -235.0% | at low | -1018.6% | at low |
Trevi Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$13.24 M(+7.4%) | -$44.20 M(+14.4%) |
| Jun 2024 | - | -$12.32 M(+13.3%) | -$38.63 M(+16.0%) |
| Mar 2024 | - | -$10.87 M(+40.1%) | -$33.30 M(+16.5%) |
| Dec 2023 | -$28.58 M(+2.1%) | -$7.76 M(+1.2%) | -$28.58 M(+9.7%) |
| Sep 2023 | - | -$7.67 M(+9.8%) | -$26.05 M(-1.1%) |
| Jun 2023 | - | -$6.99 M(+13.5%) | -$26.35 M(-2.8%) |
| Mar 2023 | - | -$6.16 M(+17.6%) | -$27.12 M(-3.1%) |
| Dec 2022 | -$27.98 M(-14.5%) | -$5.24 M(-34.3%) | -$27.98 M(-9.6%) |
| Sep 2022 | - | -$7.97 M(+2.8%) | -$30.95 M(+3.5%) |
| Jun 2022 | - | -$7.75 M(+10.4%) | -$29.92 M(-5.5%) |
| Mar 2022 | - | -$7.02 M(-14.4%) | -$31.65 M(-3.2%) |
| Dec 2021 | -$32.71 M | -$8.21 M(+18.3%) | -$32.71 M(-2.9%) |
| Sep 2021 | - | -$6.94 M(-26.9%) | -$33.69 M(-0.9%) |
| Jun 2021 | - | -$9.49 M(+17.4%) | -$33.98 M(+6.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2021 | - | -$8.08 M(-12.0%) | -$31.88 M(-1.2%) |
| Dec 2020 | -$32.27 M(+24.0%) | -$9.19 M(+27.1%) | -$32.27 M(+9.0%) |
| Sep 2020 | - | -$7.23 M(-2.2%) | -$29.62 M(-0.4%) |
| Jun 2020 | - | -$7.39 M(-12.8%) | -$29.75 M(-0.1%) |
| Mar 2020 | - | -$8.47 M(+29.7%) | -$29.77 M(+14.1%) |
| Dec 2019 | -$26.03 M(+27.1%) | -$6.53 M(-11.2%) | -$26.10 M(+2.0%) |
| Sep 2019 | - | -$7.36 M(-0.6%) | -$25.59 M(+7.0%) |
| Jun 2019 | - | -$7.41 M(+54.2%) | -$23.90 M(+12.1%) |
| Mar 2019 | - | -$4.80 M(-20.2%) | -$21.32 M(+4.2%) |
| Dec 2018 | -$20.47 M(+114.6%) | -$6.02 M(+6.0%) | -$20.47 M(+41.6%) |
| Sep 2018 | - | -$5.67 M(+17.5%) | -$14.45 M(+64.6%) |
| Jun 2018 | - | -$4.83 M(+22.2%) | -$8.78 M(+122.2%) |
| Mar 2018 | - | -$3.95 M | -$3.95 M |
| Dec 2017 | -$9.54 M | - | - |
FAQ
- What is Trevi Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for Trevi Therapeutics?
- What is Trevi Therapeutics annual EBITDA year-on-year change?
- What is Trevi Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for Trevi Therapeutics?
- What is Trevi Therapeutics quarterly EBITDA year-on-year change?
- What is Trevi Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for Trevi Therapeutics?
- What is Trevi Therapeutics TTM EBITDA year-on-year change?
What is Trevi Therapeutics annual EBITDA?
The current annual EBITDA of TRVI is -$28.58 M
What is the all time high annual EBITDA for Trevi Therapeutics?
Trevi Therapeutics all-time high annual EBITDA is -$9.54 M
What is Trevi Therapeutics annual EBITDA year-on-year change?
Over the past year, TRVI annual EBITDA has changed by -$601.00 K (-2.15%)
What is Trevi Therapeutics quarterly EBITDA?
The current quarterly EBITDA of TRVI is -$13.24 M
What is the all time high quarterly EBITDA for Trevi Therapeutics?
Trevi Therapeutics all-time high quarterly EBITDA is -$3.95 M
What is Trevi Therapeutics quarterly EBITDA year-on-year change?
Over the past year, TRVI quarterly EBITDA has changed by -$5.47 M (-70.48%)
What is Trevi Therapeutics TTM EBITDA?
The current TTM EBITDA of TRVI is -$44.20 M
What is the all time high TTM EBITDA for Trevi Therapeutics?
Trevi Therapeutics all-time high TTM EBITDA is -$3.95 M
What is Trevi Therapeutics TTM EBITDA year-on-year change?
Over the past year, TRVI TTM EBITDA has changed by -$15.61 M (-54.62%)